Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 2:17:1145-1151.
doi: 10.2147/TCRM.S330649. eCollection 2021.

Different Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Calcium Balance in Patients with Moderate to Advanced Chronic Kidney Disease

Agnieszka Makowka  1 , Michal Nowicki  1
Affiliations

Different Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Calcium Balance in Patients with Moderate to Advanced Chronic Kidney Disease

Agnieszka Makowka et al. Ther Clin Risk Manag. .

Abstract

Objective: Opposite to lanthanum carbonate (LC), sevelamer hydrochloride (SH) may increase intestinal calcium absorption. The study compared the effects of LC and SH on serum and urine phosphate and calcium, and on hormones regulating mineral-bone metabolism.

Patients and methods: A prospective randomized crossover study included 34 patients with eGFR <60 mL/min. A single oral dose of LC (1,000 mg) or SH (2,400 mg) was administered in random order 15 minutes after a standardized meal fortified with 5 g calcium carbonate. Serum calcium, phosphate, and parathormone were measured before and 3, 6, 12, and 24 hours after each medication. Bone alkaline phosphatase (BAP), sclerostin, calcitriol, and FGF-23 were measured at baseline and after 12 and 24 hours. A 24-hour calcium and phosphate excretion was measured after each drug.

Results: Serum calcium increased 3 and 6 hours after SH then returned to baseline. After LC calcium was unchanged for up to 3 hours then transiently increased and eventually returned to baseline. The area under curve (AUC) of serum calcium for 12 hours after SH was larger than after LC (p=0.04). Serum phosphate decreased after each drug with a nadir 3 hours post-SH and 6 hours post-LC. AUC of serum phosphate was similar after both medications. PTH decreased transiently after both drugs. BAP did not change. FGF-23 was constant for the first 12 hours but later decreased after each drug.

Conclusion: A 2,400 mg SH and 1,000 mg LC are similarly effective in lowering serum phosphate in CKD, but LC induce in less intestinal calcium absorption after a meal. The trial was registered on February 23, 2018 in the clinicaltrial.gov database - NCT03451019.

Keywords: PTH; calcium; chronic kidney disease – mineral bone disorder; hyperphosphatemia; phosphate-binders.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flowchart showing the study design.
Figure 2
Figure 2
Serum calcium concentration over 24 hours following a single oral dose of sevelamer or lanthanum.
Figure 3
Figure 3
Serum concentration of phosphate after a single oral dose of sevelamer or lanthanum.
Figure 4
Figure 4
Plasma concentration of PTH after a single dose of sevelamer and lanthanum.
See this image and copyright information in PMC

References

    1. Chue CD, Townend JN, Moody WE, et al. Cardiovascular effect of sevelamer in stage 3 in CKD. J Am Soc Nephrol. 2013;24:842–852. doi:10.1681/ASN.2012070719 - DOI - PMC - PubMed
    1. Demer L, Tintut Y. The bone-vascular axis in chronic kidney disease. Curr Opin Nephrol Hypertens. 2010;19:349–353. doi:10.1097/MNH.0b013e32833a3d67 - DOI - PMC - PubMed
    1. Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72:1255–1261. doi:10.1038/sj.ki.5002518 - DOI - PubMed
    1. Yono S, McKee MD, Murry C, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;29:E10–E17. - PubMed
    1. Hrushka KA, Mathew S. The role of the skeleton and phosphorus in the CKD mineral bone disease. Adv Chronic Kidney Dis. 2011;18:98–104. doi:10.1053/j.ackd.2011.01.001 - DOI - PMC - PubMed

Associated data